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MHC anchor residue-modified “heteroclitic” peptides have been used inmany cancer vac-
cine trials and often induce greater immune responses than the wild-type peptide. The
best-studied system to date is the decamer MART-1/Melan-A26–35 peptide, EAAGIGILTV,
where the natural alanine at position 2 has been modified to leucine to improve human
leukocyte antigen (HLA)-A*0201 anchoring. The resulting ELAGIGILTV peptide has been
used in many studies. We recently showed that T cells primed with the ELAGIGILTV pep-
tide can fail to recognize the natural tumor-expressed peptide efficiently, thereby provid-
ing a potential molecular reason for why clinical trials of this peptide have been unsuc-
cessful. Here, we solved the structure of a TCR in complex with HLA-A*0201-EAAGIGILTV
peptide and compared it with its heteroclitic counterpart , HLA-A*0201-ELAGIGILTV. The
data demonstrate that a suboptimal anchor residue at position 2 enables the TCR to “pull”
the peptide away from the MHC binding groove, facilitating extra contacts with both the
peptide and MHC surface. These data explain how a TCR can distinguish between two
epitopes that differ by only a single MHC anchor residue and demonstrate howweakMHC
anchoring can enable an induced-fit interaction with the TCR. Our findings constitute a
novel demonstration of the extreme sensitivity of the TCR to minor alterations in peptide
conformation.
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Introduction
CD8+ T cells can exploit the major histocompatibility com-
plex class I (MHCI) peptide presentation pathway to interro-
gate the cellular proteome and identify aberrant gene expression
within cancer cells. These cytotoxic cells then eliminate tumor
cells directly using an arsenal of granule-relayed and receptor-
mediated cell death machinery; properties that have made CD8+
T cells an attractive target for therapeutic cancer vaccination
[1]. An effective CD8+ T-cell response requires that the cell sur-
face expressed TCR binds to its cognate peptide-MHCI (pMHCI)
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molecule with sufficient affinity/duration to induce cellular acti-
vation [2, 3]. We have demonstrated that TCRs bind more weakly
to cancer epitopes compared to pathogenic epitopes [4, 5]. This
important difference probably arises because most cancer epi-
topes are derived from self-molecules. Thus, potential cancer-
specific T-cell clones with higher affinity TCRs are probably nega-
tively selected against during the thymic auditioning process that
has evolved to limit autoimmunity. Effective T-cell peptide epi-
topes are also required to form a stable interaction with MHCI
[6]. The MHCI peptide-binding groove has several chemically
distinct-binding pockets (termed A–F) [7–9]. Interaction between
∗These authors contributed equally to this study.
C© 2014 The Authors. European Journal of Immunology Published byWiley-VCH Verlag GmbH & Co. KGaA,
Weinheim
www.eji-journal.eu
This is an open access article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original work is properly
cited.
2 Florian Madura et al. Eur. J. Immunol. 2014. 00: 1–8
peptide and MHCI is principally governed by primary peptide
anchor residues that are generally located toward the N- and C-
terminus (MHCI-binding pockets B and F). This binding modal-
ity allows most MHCI molecules to present peptides of differ-
ing lengths by accommodating the extra amino acids as a central
“bulge” within the binding groove [10, 11]. The extreme diver-
sity of human MHCI genes [12] is focused upon these binding
pockets so that different MHCIs have distinct optimal peptide-
binding parameters, allowing them to interact with, and present,
different subsets of peptides to T cells. The majority of cancer
peptide epitopes that have been described do not contain optimal
primary peptide anchor residues and many studies have focused
upon modifying these residues (generating so called “heteroclitic”
peptides) to improve the stability of these cancer epitopes at the
cell surface [1, 13–16]. Because the TCR generally focuses on the
central portion of the peptide (the so called “peptide bulge”) dur-
ing antigen recognition [17, 18], modification at buried terminal
amino acids were not thought to alter TCR binding. However, we
have recently shown that the TCR can detect these changes in
peptide sequence [19]. This fundamental observation is critical
to the development of MHC anchor modified peptides, because
vaccination using these reagents could lead to the targeting of
T cells that can recognize the modified peptide, but not the nat-
ural peptide present on the surface of tumors. This observation
could be a central factor in explaining why many clinical trials
using heteroclitic peptides to treat cancer have failed.
Our previous study [19] focused on an HLA-A*0201 restricted
Melan-A/MART-126–35 (EAAGIGILTV) antigen (A2-EAA) [20].
The anchor-residue-modified heteroclitic version of this peptide,
ELAGIGILTV (A2-ELA), is the most commonly described human
tumor-related MHCI-restricted epitope in the current literature
and has been shown to induce a far greater expansion of T cells
when used in vaccination trials compared to A2-EAA [21, 22].
Despite A2-EAA inducing less than half of the response seen with
A2-ELA, T cells primed with the natural antigen were found to
have stronger tumor reactivity [23]. Analysis of the TCRs selected
after vaccination of melanoma patients with these two pep-
tides revealed subtle differences in the repertoire [24]. Our own
clonotypic analysis of in vitro-expanded T-cell populations also
showed that distinct T-cell clonotypes were generated depend-
ing on whether A2-ELA, or A2-EAA was used [19]. Molecular
analysis highlighted that, although A2-ELA is more stable than
A2-EAA, T cells can distinguish between these variants in cellu-
lar assays [19]. The MEL5 TCR bound to A2-ELA relatively weakly
(KD = 17–18 μM) [4, 19, 25] by surface plasmon resonance (SPR)
compared to A2-EAA (KD = 6.4 μM) [19]. Collectively, these find-
ings could represent a major caveat to using A2-ELA for therapeu-
tic melanoma vaccination because it can prime T cells that may
not then respond optimally to natural tumor epitope.
Here, we set out to establish the molecular mechanism by
which a TCR could distinguish between A2-EAA and A2-ELA. The
atomic structures of these peptides in complex with HLA*0201
have been solved previously [26]. Both peptides adopt an identical
bulged conformation, revealing no obvious mechanism for how a
TCR could discriminate between them. The crystallographic struc-
Figure 1. Thermodynamic signature of the MEL5-A2-EAA interaction.
Binding affinity and thermodynamic analyses of the MEL5-A2-EAA
interaction was performed using SPR. (A, B) The binding affinity of
MEL5 for (A) A2-ELA and (B) A2-EAA were reproduced from [19, 25] by
equilibrium analysis. (C) Thermodynamic analysis of the MEL5-A2-ELA
interaction were reproduced from [25]. (D) Thermodynamic analysis of
the interaction between MEL5 and A2-EAA was determined by SPR. KDs
were measured in triplicate at 5, 10, 15, 20, 25, and 30°C with ten serial
dilutions of MEL5 (Supporting Information Fig. 1); representative data
from a single experiment is plotted. HLA-A*0201-ILAKFLHWL was used
as a negative control surface on flow cell 1. The binding free energies
(G = RT ln KD) were plotted against temperature and the thermo-
dynamic parameters (H° and TS°) were calculated according to the
nonlinear van’t Hoff equation (RT ln KD = H° – TS° + Cp°(T - T0) –
TCp° ln (T/T0)).
tures of DMF4 and DMF5 [27], the first TCRs used in TCR gene
transfer and adoptive cell therapy for cancer, and MEL5 TCR [25]
in complex with the A2-ELA have been solved. To date there is no
atomic structure of the natural A2-EAA peptide in complex with
a TCR. Here, we fill this important knowledge gap by solving the
atomic structure of the MEL5-A2-EAA complex and performing an
in-depth biophysical analysis to determine the molecular mecha-
nism for altered T-cell recognition between A2-ELA and the tumor
expressed A2-EAA antigen by the MEL5 T cell. These data demon-
strate the extreme sensitivity of the TCR to minor conformational
changes in the peptide, extend our understanding of CD8+ T-cell
recognition of a prominent tumor target and have important impli-
cations for the design of altered peptide ligands for use in cancer
vaccination.
Results
MEL5 binds to A2-EAA with a distinct thermodynamic
signature
The affinity of MEL5 for A2-ELA and A2-EAA has been described
previously [19] and reproduced here (Fig. 1A and B). These data
demonstrate that, although the modification to this peptide is
located at peptide anchor residue 2 that does notmakemajor inter-
actions with the MEL5 TCR [25], the affinity of the MEL5-A2-EAA
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interaction is more than twice as strong as the MEL5-A2-ELA inter-
action [19]. This distinction has important implications for the
use of the heteroclitic A2-ELA peptide in vaccination as previously
described [19, 23, 24]. The structures of A2-ELA (PDB: 1JF1) and
A2-EAA (PDB: 2GT9) provided no obvious reason for why a TCR
could distinguish between them [26]. In order to determine the
mechanism for how the MEL5 TCR bound to these peptides with
over twofold difference in affinity, we performed a thermodynamic
analyses of the MEL5-A2-EAA interaction and compared it to data
for A2-ELA [25] (Fig. 1C). These data demonstrated that MEL5
bound to A2-ELA with favorable entropy (TS° = 8.4 kcal/mol)
and unfavorable enthalpy (H° = 2 kcal/mol), suggesting that
a transition from order to disorder, possibly through the expul-
sion of ordered water molecules, was the major driving force
during binding. Surprisingly, and in contrast to the MEL5-A2-
ELA interaction, the MEL5-A2-EAA interaction was enthalpi-
cally driven (H°  –14 kcal/mol) and entropically unfavorable
(TS°  –7.2 kcal/mol) (Fig. 1D and Supporting Information
Fig. 1), similar to that observed for other TCR-pMHC interactions
[28]. These findings demonstrate a distinct energetic footprint for
the MEL5-A2-EAA interaction, suggesting that a net formation of
new electrostatic interactions drove the formation of the complex.
MEL5 binds to A2-ELA and A2-EAA with similar
conformation
In order to further understand the mechanism underlying the dif-
ference in T-cell recognition of the natural versus the heteroclitic
MART-1/Melan-A26–35 peptide, we solved the crystal structure of
MEL5 complexed to A2-EAA (Table 1). The MEL5 TCR bound in a
canonical diagonal docking mode at a crossing angle of47°, with
shape complementarity and buried surface area within the range
described for other published TCR-pMHC interactions (Table 2)
[18, 29]. Superposition of the MEL5-A2-ELA and MEL5-A2-EAA
structures, using the MHC molecule to align, demonstrated a
similar-binding conformation (Fig. 2A) with the TCR CDR loops
positioned identically over the MHC-binding groove (Fig. 2B). The
contact footprint of the TCR over both surfaces was also similar,
but not identical (Fig. 2C and D), with MEL5 contacting more
residues on the surface of A2-EAA than A2-ELA. Concordantly, the
TCR residues utilized for binding were very similar in each case
(Fig. 2E and F), but again more TCR residues were involved in
binding to A2-EAA than A2-ELA. These data demonstrate that the
molecular mechanism explaining the difference in TCR-binding
affinity and thermodynamics was not due to a large difference
in binding orientation of the MEL5 TCR and warranted a more
detailed investigation of the binding interface.
N-terminal peptide flexibility enables additional
contacts between A2-EAA and the MEL5 TCR
In both theMEL5-A2-EAA andMEL5-A2-ELA structures, themajor-
ity of the contacts were made in the central region of the peptide
Table 1. Data collection and refinement statistics (molecular
replacement)
Dataset statistics MEL5-A2-EAA
PDB 4QOK
Space group P41
Unit cell parameters (A˚) a = 121.40, b = 121.40, c = 82.32
Radiation source DIAMOND I04–1
Wavelength (A˚) 0.9173
Resolution (A˚) 41.03–3.00 (3.08–3.0)
Unique reflections 22 733 (1726)
Completeness (%) 99.9 (99.9)
Multiplicity 7.5 (7.9)
I/Sigma(I) 12.8 (3.1)
Rmerge 0.122 (0.820)
Refinement statistics
No reflections used 22 556
No reflections in Rfree
set
1219
Rcryst (no cutoff) (%) 20.3
Rfree (%) 26.2
RMSD from ideal geometry
Bond lengths (A˚) 0.013
Bond angles (°) 1.452
Mean B value (A˚2) 70.8
Wilson B-factor (A˚2) 78.4
ESU based on maximum
likelihood (A˚)
0.31
ESU for B values based
on maximum
likelihood (A˚2)
16.3
One crystal was used for data collection.
Number in parentheses indicate the outer-resolution shell.
Table 2. Detailed analysis of MEL5-A2-EAA versus MEL5-A2-ELA
structures
MEL5-
A2-EAA
MEL5-
A2-ELA [25]
Total No. TCR-pMHC contactsa) 12/104 7/86
No. Vα contactsa) 7/49 4/44
No. Vβ contactsa) 5/55 3/42
No. TCR-peptide contactsa) 6/39 3/33
No. TCR-MHC contactsa) 6/65 4/53
BSAb) (A˚2) 2366 2528
SCc) (%) 59.9/74.5/64 73.1/56/66.6
Crossing angle (°) 46.9 42.6
a)Number of hydrogen bonds (H-bond) (3.4A˚) and salt bridges
(3.4A˚)/van der Waals (vdW) (3.2–4A˚) contacts calculated with the
CONTACT program from the CCP4 package.
b)Buried surface area (BSA) (A˚2) calculated with PISA program from the
CCP4 package.
c)Shape complementarity (SC) (%) of TCR-MHC/TCR-peptide/TCR-pMHC
calculated with SC program from the CCP4 package.
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Figure 2. MEL5 utilizes an identical general binding mode to A2-
EAA and A2-ELA. The MEL5-A2-EAA complex structure was solved
with molecular replacement using PHASER [47]. The model sequence
was adjusted with COOT [48] and the model refined with REFMAC5.
(A) Superposition of the MEL5 V domain interacting with either A2-EAA
(orange cartoon) or A2-ELA [25] (yellow cartoon). (B) Superposition of
the MEL5 CDR loops interacting with either A2-EAA (orange cartoon)
or A2-ELA (yellow cartoon). (C, D) MHC residues contacted by the MEL5
TCR are shown interacting with either (C) A2-EAA (orange surface) or
(D) A2-ELA (yellow surface). (E, F) TCR residues used during the inter-
action with either (E) A2-EAA (orange balls) or (F) A2-ELA (yellow balls).
Data shown were generated from one crystal.
(residues P4–P7) (Supporting Information Table 1). The MEL5 Vα
domain contacted peptide residues P1–P5, predominantly through
the TCR CDR1α loop (Fig. 3, Supporting Information Tables 1
and 2). This is distinct from the generally observed TCR-peptide
interaction that is normally dominated through the TCR CDR3
loops [30]. The MEL5 Vβ domain contacted residues P5–P9, with
TCR CDR3β aligning alongside the C-terminal half of the pep-
tide, as seen with the DMF4 TCR [27]. Although all three MHC
restriction triad residues [10] (Arg65, Ala69, and Gln155) were
involved in the interaction between MEL5 TCR and A2-ELA, only 2
(Arg65 and Gln155) formed bonds in the MEL5-A2-EAA complex
(Supporting Information Tables 1 and 2). In agreement with the
distinct thermodynamic signature (Fig. 1), MEL5 made more con-
tacts with A2-EAA (eight hydrogen bonds, four salt bridges, and
104 vdW interactions) than with A2-ELA (five hydrogen bonds,
two salt bridge, and 104 vdW interactions). The greater number
of bonds between MEL5 and A2-EAA also offers an explanation for
the stronger affinity between these two molecules. Although the
overall conformation of the two complexes was similar (Fig. 2),
on closer inspection it was evident that the N-terminus of the
EAA peptide extended 0.9A˚ closer to the MEL5 TCR compared
to the uncomplexed A2-ELA and A2-EAA structures [26] and the
MEL5-A2-ELA complex (Fig. 3A) [25]. This conformational dis-
tinction was possible because the smaller alanine side chain at
position 2 in the EAA peptide made a less optimal interaction with
the B pocket of the HLA A*0201 molecule, compared to the longer
leucine side chain in the ELA peptide. This difference also explains
our previous observation demonstrating that the A2-EAA complex
is less stable than A2-ELA [19]. Thus, MEL5 was able to “pull”
the N-terminus of the EAA peptide away from the MHC surface
and make a different network of contacts compared to A2-ELA.
Overall, MEL5 made three hydrogen bonds and four vdW interac-
tions with EAA peptide residues Glu1 and Ala2, compared to only
two vdW interactions with ELA peptide residues Glu1 and Leu2
(Fig. 3B and C). In addition to the differences in peptide contacts,
MEL5 also made distinct contacts with the MHC surface in the
MEL5-A2-EAA complex. MHC residue Arg65 underwent a 1.8A˚
movement between the two complex structures, coupled with a
4.8A˚ movement in TCRα chain residue Tyr51 (Fig. 3D). These
movements enabled MEL5 residues αAla94 and βTyr49 to make
two salt bridges and nine vdW interactions with MHC residue
Arg65 (compared to one salt bridges and three vdW interactions
for A2-ELA) and TCR residue βLeu98 to make five vdW con-
tacts with MHC residues Ala69 and His70 (compared to none for
A2-ELA) in the MEL5-A2-EAA complex (Fig. 3E and F). These data
show that small changes in peptide flexibility can lead to substan-
tially different TCR contacts. These structural observations offer a
novel molecular mechanism that explains the differences in TCR-
binding affinity and T-cell recognition that we [19], and others
[23], have previously observed between A2-EAA and A2-ELA.
Discussion
Themajority of tumor-derivedMHCI-associated peptides that have
been described as T-cell epitopes have suboptimal anchor residues
[1]. This observation might be because self-antigens that bind
tightly to MHC are presented at higher concentrations in the
thymus, leading to stronger T-cell activation and negative selec-
tion. It is possible that tumor-derived peptides with poor MHC
anchors exhibit reduced cell surface expression levels in the thy-
mus, thereby generating weak T-cell activation and positive selec-
tion. This notion has also been suggested for a number of T-cell
responses to autoantigens where the auto-peptide bound weakly
to MHC [31, 32]. In addition, tumor-specific T cells generally
have weakly binding TCRs [4, 5]. These factors combine with var-
ious immunosuppressivemechanismswithin tumors to ensure that
T-cell responses to neoplastic cells are often poor. To overcome
this lack of immunogenicity, a number of anchor residue modified
“heteroclitic” peptides have been developed where amino acids
in the natural sequence that act as weak primary MHC anchors
are substituted for optimal anchors [1, 13–16]. A requirement of
these reagents is that they should not alter T-cell specificity, or
C© 2014 The Authors. European Journal of Immunology Published by
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Figure 3. Altered anchoring of peptide to MHC
changes TCR contacts. The MEL5-A2-EAA complex
structure was analyzed using the program CONTACT
from the CCP4 software suite and graphical represen-
tation was prepared using PYMOL. (A) The position of
the EAApeptide (cyan sticks) compared to the ELApep-
tide (blue sticks) in complex with theMEL5 TCR (MEL5-
A2-EAA; orange and MEL5-A2-ELA; yellow sticks) is
shown. (B) Hydrogen bonds (red dotted lines) and vdW
contacts (black dotted lines) are shown between the
EAA peptide (cyan sticks) and theMEL5 TCR CDR1 loop
(orange sticks). (C) Hydrogen bonds and vdW contacts
are shown between the ELA peptide (blue sticks) and
the MEL5 TCR CDR1 loop (yellow sticks). (D) The posi-
tion of MHCα1 (gray cartoon) residue Arg65 and MEL5
α chain residue Tyr51 in the MEL5-A2-EAA complex
(orange sticks) compared to theMEL5-A2-ELA complex
(yellow sticks). (E) Hydrogen bonds and vdW contacts
are shown between the MEL5 TCR (orange cartoon)
and the MHCα1 helix (gray cartoon) in the MEL5-A2-
EAA complex. (E) Hydrogen bonds and vdW contacts
are shown between the MEL5 TCR (yellow cartoon)
and the MHCα1 helix (gray cartoon) in the MEL5-A2-
ELA complex. Data shown were generated from one
crystal.
the T cells selected with the heteroclitic peptide may not respond
to the peptide expressed at the tumor cell surface in vivo. Con-
sistent with this notion, previous studies have demonstrated the
importance of designing heteroclitic peptides that are the closest
structural mimics of the original wild-type peptide [33]. Because
the TCR does not usually contact the anchor residues directly
[18], the assumption has been that anchor residue modifications
should not be detected by the TCR. However, we have recently
shown that T cells can distinguish between peptides with mod-
ified anchors, and these heteroclitic peptides can activate a dis-
tinct T-cell population that does not recognize the unmodified
tumor-expressed peptide [19]. Importantly, different efficacies
and TCR repertoires have been observed between natural and het-
eroclitic mimitopes during cancer vaccine trials [23, 24] offering
a potential explanation for why some of these vaccine trials have
failed.
Here, we reveal the structural mechanism for changes in TCR
specificity mediated by the commonly used heteroclitic peptide
in the HLA-A*0201-restricted MART-1/Melan-A26–35 system. Sev-
eral studies have shown that TCRs can distinguish between the
natural HLA-A*0201-EAAGIGILTV antigen and the HLA-A*0201-
ELAGIGILTV variant [19, 23, 24]. The structures of these two
molecules have provided no obvious reason for why TCRs could
distinguish between them [26]. We find that although the MEL5
TCR bound with an identical overall conformation to A2-EAA and
A2-ELA, the weaker anchor residue at position 2 in the natural
peptide enabled the TCR to “pull” the peptide away from the
MHC peptide-binding groove. This small movement facilitated
nine extra contacts with the peptide, and indirectly led to 14
extra contacts with the MHC surface compared to the MEL5-A2-
ELA interaction. These extra bonds explain the stronger binding
affinity for the MEL5-A2-EAA interaction and demonstrate the
sensitivity of the TCR for detecting changes in the peptide, in
line with our previous findings [34, 35]. Our previous thermo-
dynamic experiments demonstrated that MEL5 bound to A2-ELA
with favorable entropy and unfavorable enthalpy [25], suggest-
ing that a transition from order to disorder, possibly through the
expulsion of ordered water molecules, mediated the interaction.
In contrast, MEL5 bound to A2-EAA with favorable enthalpy sug-
gesting that, consistent with our structural observations, a net
increase in electrostatic interactions drove binding. Thus, MEL5
bound to A2-EAA with a distinct energetic signature compared to
A2-ELA (entropically favorable; order to disorder driven) that was
enthalpically favorable, demonstrated by the increase in interac-
tions we observed at the MEL5-A2-EAA interface, which medi-
ated the stronger binding affinity compared to MEL5-A2-ELA. The
observation that an increase in TCR-binding affinity is associated
with a switch from favorable entropy to favorable enthalpy is con-
sistent with findings from other studies [36].
In summary, we demonstrate that peptides with suboptimal
anchor residues can be more flexible within the MHC-binding
groove, thereby enabling them to form subtly different confor-
mational motifs that have an effect on the fine specificity of
the TCR. In the case of MEL5, we previously hypothesized that
increased flexibility in the P1–P2 region of the peptide might
allow for stronger, or even new, TCR-peptide contacts that could
explain the enhanced TCR affinity and preferential antigen sensi-
tivity of MEL5 for A2-EAA (KD = 6.4 μM) compared with A2-ELA
(KD = 17–18 μM). The MEL5-A2-EAA structure confirms this
hypothesis. These data constitute a novel demonstration of the
extreme sensitivity of the TCR to minor alterations in peptide con-
formation, extending our understanding of the molecular intrica-
cies of T-cell antigen recognition with attendant implications for
the design of altered peptides for therapy. Future use of altered
peptide ligands for breaking tolerance to cancer epitopes will
require rigorous testing to ensure that these peptides skew the
TCR repertoire that is primed toward beneficial clonotypes that
have a strong reactivity toward the natural epitope [37–40].
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Materials and methods
Generation of the MEL5 TCR
The MEL5 TCR was derived from the MEL5 CD8+ T-cell clone spe-
cific for HLA-A*0201 MART-1/Melan-A26–35 (EAAGIGILTV) [25].
Cloning and expression
The MEL5 TCR α and MEL5 TCR β chains, HLA-A*0201 heavy
chain and β2m sequences were cloned into the pGMT7 expression
vector under the control of the T7 promoter as described previ-
ously [41]. The MEL5 TCR α and MEL5 TCR β chains, the HLA
A*0201 α chain, and β2m were expressed separately in competent
Rosetta DE3 Escherichia coli cells as described previously [42].
Refolding and purification
Refolding was performed as previously described [4]. Briefly,
for a 1 L MEL5 TCR refold, 30 mg of MEL5 α-chain was incu-
bated at 37°C for 30 min with 10 mM DTT and added to refold
buffer at 4°C (50 mM TRIS pH 8.1, 2 mM EDTA, 2.5 M urea,
6 mM cysteamine hydrochloride, and 4 mM cystamine). After 30
min, 30 mg MEL5 β-chain, also incubated at 37°C for 30 min with
10 mM DTT, was added. For a 1 L pMHCI refold, 30 mg HLA
A*0201 α-chain was mixed with 30 mg β2m and 4 mg EAAGIG-
ILTV peptide at 37°C for 30 min with 10 mM DTT. This mixture
was then added to refold buffer at 4°C (50 mM TRIS pH 8.1, 2 mM
EDTA, 400 mM L-arginine, 6 mM cysteamine hydrochloride, and
4 mM cystamine). The MEL5 TCR and A2-EAA refolds were mixed
at 4°C for 1–3 h and dialyzed against 10 mM TRIS pH 8.1 until
the conductivity of the refolds was <2 mS/cm. Refolded proteins
were purified by ion exchange using a Poros50HQTM column (GE
Healthcare, Buckinghamshire, UK) and gel filtered into crystal-
lization buffer (10 mM TRIS pH 8.1 and 10 mM NaCl) or BIAcore
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, and
0.005% v/v surfactant P20) using a Superdex200HRTM column
(GE Healthcare, Buckinghamshire, UK).
Protein crystallization
Crystals were grown at 18°C by vapor diffusion via the sitting
drop technique as previously described [43]. For MEL5-A2-EAA,
optimal crystals were obtained in TOPS [44] with 0.1 M Sodium
cacodylate pH 6.5, 15% PEG 4000, and 15% glycerol.
Structure determination and refinement
Diffraction data were collected at a beamline I0–2 at the Diamond
Light Source, Oxford, using a Pilatus 2M detector, a QADSC detec-
tor or a Rayonix detector. Using a rotation method, 400 frames
were recorded each covering 0.5° of rotation. Reflection intensi-
ties were estimated with the XIA2 package [45] and the data were
scaled, reduced, and analyzed with SCALA and the CCP4 package
[46]. The TCR-pMHC complex structure was solved with molec-
ular replacement using PHASER [47]. The model sequence was
adjusted with COOT [48] and the model refined with REFMAC5
[49]. Accession code PDB: 4QOK.
pMHC biotinylation
Biotinylated pMHCs were prepared as described previously [4].
Surface plasmon resonance analysis
Binding analysis was performed using a BIAcore T100TM equipped
with a CM5 sensor chip as previously described [19]. MEL5 was
purified and concentrated to150 μM on the same day of surface
plasmon resonance analysis to reduce the likelihood of TCR aggre-
gation affecting the results. For equilibrium analysis, ten serial
dilutions were prepared in triplicate for each sample and injected
over the relevant sensor chips at 25°C. MEL5 was injected over the
chip surface using kinetic injections at a flow rate of 45 μL/min
using HLA-A*0201-ILAKFLHWL as a negative control surface. For
the thermodynamics experiments, this method was repeated at
the following temperatures: 5, 10, 15, 20, 25, and 30°C. Results
were analyzed using BIA evaluation 3.1, Excel, and Origin 6.0
software. The equilibrium-binding constant (KD) values were cal-
culated assuming a 1:1 interaction by plotting specific equilibrium-
binding responses against protein concentrations followed by
nonlinear least squares fitting of the Langmuir-binding equation.
The thermodynamic parameters were calculated using the nonlin-
ear van’t Hoff equation (RT ln KD = H° – TS° + Cp°(T – T0)
– TCp° ln (T/T0)) with T0 = 298 K.
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